> ## Content Index > Fetch the complete content index at: https://www.tao.media/llms.txt > Use this file to discover other available public pages before exploring further. # Anthropic Acquires Mithril Medicine as Six Partners Report Claude Drug-Development Results - URL: https://www.tao.media/anthropic-acquires-mithril-medicine-as-six-partners-report-claude-drug-development-results/ - Published: 2026-10-28T13:36:48.000Z - Updated: 2026-10-28T13:36:50.000Z - Description: Early findings span antibody design, manufacturing paperwork, and trial planning as Anthropic expands its own rare-disease research. - Author: Bart Hillerich - Tags: Anthropic, Mithril Medicine, AI, News Anthropic has acquired Mithril Medicine, a one-person biotechnology company developing treatments for two rare forms of muscular dystrophy, and released early results from six research partnerships using Claude across the drug-development process. The work covers designing cancer therapies and food-allergy antibodies, reviewing manufacturing records, and planning clinical trials. In its [research update](https://www.anthropic.com/research/early-progress-drug-development?ref=tao.media), Anthropic and its partners reported laboratory improvements in experimental molecules alongside reductions in time spent on documentation. Most of the research remains preclinical, with the drug candidates not yet being tested in people. The six partners are BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group. Anthropic plans to [expand the research substantially](https://x.com/AnthropicAI/status/2115178675050307942?ref=tao.media), using work inside real drug programs to improve Claude and identify bottlenecks beyond initial molecule design. ## Redesigning Cancer Therapies and Allergy Antibodies At Generate Biomedicines, six scientists used Claude Code to redesign part of the genetic instructions for a CAR T-cell therapy. These treatments equip immune cells with receptors that recognize cancer cells. Generate aims to adapt an approach historically used against blood cancers for solid tumors. Shortening part of those instructions could create space for additional functions needed to treat other cancers. One Claude-assisted design was about 70% shorter than the standard version. Generate reported that, in laboratory tests, it enabled immune cells to produce roughly 10 times as many receptors, kill tumor cells more efficiently, and remain active for longer. Its [technical report](https://generatebiomedicines.com/publications/refactored-intracellular-domains-enhance-car-expression-and-function/?ref=tao.media) details the redesigned receptor components and their performance. Divergence Labs is pursuing a different problem: removing the allergy-associated molecule IgE from immune cells. Standard medications neutralize IgE circulating in the blood; Divergence wants a drug that can also detach IgE already bound to cells. The proposed molecule needs two functional arms, one to bind tightly to IgE and another to help dislodge it. Claude translated that objective into a design plan and then generated roughly 35,000 antibody designs, largely autonomously, in about a month. Early testing identified three designs that bound IgE and 20 that dislodged it. Three of the latter appeared to remove more IgE than the standard medication in those tests. Divergence’s next step is to [combine the two arms into one drug](https://divergencelabs.com/publications/ige-preprint.pdf?ref=tao.media). ## Improving Molecules and Manufacturing Reviews BigHat Biosciences connected Claude to its laboratory data system, Reccy, to improve two antibody fragments: one intended to target cancer cells and another intended to keep a drug in the body longer. Such fragments could become components of future medicines, but they need properties beyond target binding, including stability and resistance to clumping. Claude proposed molecular changes, and BigHat’s automated laboratory made and tested about 1,010 variants over roughly 10 weeks. The best versions bound their targets more than 10 times as tightly as the originals. The cancer-targeting lead stayed in solution at a temperature 18 degrees Celsius higher, while the fragment intended for longer-lasting drugs clumped more than 100 times more slowly. The collaboration also changed how the team measured progress. When an Anthropic researcher and Claude suspected that standard heat-stability and aggregation measurements were misleading, they reanalyzed the raw data and proposed alternative metrics and a revised testing protocol. BigHat’s scientists refined and ran the experiment, and the main predictions held, according to the [collaboration report](https://www.bighatbio.com/bighat-anthropic-collaboration-report-10-27-2026?ref=tao.media). At Enveda, the focus was the paperwork required to manufacture drugs consistently and seek permission for clinical trials. Manufacturing chemists had been spending up to 75% of their time on documentation. Enveda connected its manufacturing documents to Claude so the model could flag potential problems. Across 1,061 pages, the system caught all 11 issues found by human reviewers and flagged seven they had missed. Human review time fell 89%, from more than 25 hours to less than three. Claude also produced first drafts of two regulatory documents. One took four hours rather than the roughly three months required manually. For the other, Enveda’s standard human review identified one minor error. Enveda describes the workflow in its [technical report](https://enveda.com/CMC-Document-Processor/?ref=tao.media). ## Smaller Teams and Clinical Planning The Column Group is establishing Pleiades, a company intended to use Claude to let a small team manage more drug programs, including more complex ones. The aim is to reduce scientific, operational, and administrative overhead enough to make ambitious research programs more practical to fund and run. Pleiades is developing Claude tools and workflows for that model. Its first skill, which helps assess whether a drug target is worth pursuing, has been evaluated on 45 target-disease pairs. Bristol Myers Squibb is working further along the development process. It is using Claude to assess development plans for an early-stage drug already in clinical trials and estimate the trials’ likelihood of success. Michael Pourdehnad, BMS’s head of early clinical development for hematology, oncology, and cell therapy, said a single prompt generated an initial analysis that helped the team compare development options, work that would otherwise take days. BMS and Anthropic plan to expand the collaboration in 2027, including exploring how the approach could support decisions across a drug pipeline. ## Mithril Brings Rare-Disease Programs Inside Anthropic Mithril Medicine founder Cody Tranbarger used Claude to coordinate contracts, logistics, and experiments involving 11 external laboratories, while delegating much of the company’s other operational work to the model. The company advanced a potential muscular dystrophy treatment from an idea to promising results in mice in less than 18 months. The acquisition puts Tranbarger and those research programs inside Anthropic. He is continuing the muscular dystrophy work and plans to start several additional programs. Anthropic has published a [technical report on the research](https://www-cdn.anthropic.com/52e1f5d50c47ca3818f56704c27cf19e59b62e77.pdf?ref=tao.media). The deal follows OpenAI’s acquisition of Orchestra Bio, which adds agents for coordinating studies and drug programs to Rosalind. Anthropic’s acquisition brings experimental treatment programs in-house, alongside its work supplying Claude to external research teams. [OpenAI Acquires Orchestra Bio to Add Drug-Development Coordination to RosalindThe deal brings AI agents for tracking studies and managing drug programs into OpenAI’s life sciences business.![](https://storage.ghost.io/c/78/0b/780ba906-b1a7-4bf0-873c-bdd5c32e5331/content/images/icon/Group-1321319358-76ecdf07-3bf0-41fa-8fb1-2a289b054e54.png)Intelligence![](https://storage.ghost.io/c/78/0b/780ba906-b1a7-4bf0-873c-bdd5c32e5331/content/images/2026/10/openai-orchestra-bio-hero.png)](https://www.tao.media/openai-acquires-orchestra-bio-to-add-drug-development-coordination-to-rosalind/) Anthropic also offers Claude Science, a research workbench, credits for life scientists, and a Life Sciences Verification Program that gives verified organizations access to more permissive safeguards for legitimate biological research. It plans to extend Claude’s role into clinical trials as partner programs advance and to work with more organizations already conducting human studies. For Mithril’s candidates, Anthropic expects a drug could be ready to begin human clinical trials as soon as late 2028, provided the candidates continue to hold up in further research.